- Record: found
- Abstract: found
- Article: not found
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Bella Kaufman
1 ,
John R Mackey ,
Michael R Clemens ,
Poonamalle P Bapsy ,
Ashok Vaid ,
Andrew Wardley ,
Sergei Tjulandin ,
Michaela Jahn ,
Michaela Lehle ,
Andrea Feyereislova ,
Cédric Révil ,
Alison Jones
Nov 20 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor-copositive metastatic breast cancer (MBC).